Eur J Endocrinol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


DOI: 10.1530/eje.0.1470381
European Journal of Endocrinology, Vol 147, Issue 3, 381-386
Copyright © 2002 by European Society of Endocrinology
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Chatzistamou, I
Right arrow Articles by Koutselini, H
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chatzistamou, I
Right arrow Articles by Koutselini, H

Articles

Expression of growth hormone-releasing hormone in human primary endometrial carcinomas

I Chatzistamou, AV Schally, A Pafiti, H Kiaris, and H Koutselini

Department of Pathology, Aretaieion University Hospital, Medical School, University of Athens, Vassilisis Sofias 76, Athens 11528, Greece.

BACKGROUND: Hypothalamic GH-releasing hormone (GHRH) regulates GH release from the pituitary, but an ectopic production of GHRH has been detected in various non-hypothalamic tissues, especially cancers. OBJECTIVE: To investigate whether endometrial tumors produce GHRH. METHODS: Twenty-four endometrioid, three serous papillary (SP), three mixed type endometrioid/serous papillary adenocarcinomas and one malignant mixed Mullerian tumor (MMMT) were assessed for GHRH immunoreactivity by the polyclonal anti-rabbit antibody SV95 and for the expression of GHRH mRNA by in situ hybridization using an oligonucleotide probe. RESULTS: Increased GHRH immunoreactivity was detected in 15 out of 24 (63%) of the endometrioid tumors, including two out of three (66%) of the mixed type endometrioid/serous adenocarcinomas but not in the three SP or the MMMT tumor. Cytoplasmic staining was detected in all positive cases, while in three of them strong nuclear localization of GHRH was also revealed. In situ hybridization indicated the presence of GHRH mRNA in six cases, all characterized as positive for GHRH immunoreactivity. CONCLUSION: GHRH is expressed in a subset of endometrial tumors, of the endometrioid type in particular. A paracrine/autocrine role for GHRH in the development of the disease should be considered.


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
H. Kiaris, K. Politi, L. M. Grimm, M. Szabolcs, P. Fisher, A. Efstratiadis, and S. Artavanis-Tsakonas
Modulation of Notch Signaling Elicits Signature Tumors and Inhibits Hras1-Induced Oncogenesis in the Mouse Mammary Epithelium
Am. J. Pathol., August 1, 2004; 165(2): 695 - 705.
[Abstract] [Full Text] [PDF]


Home page
Proc. Natl. Acad. Sci. USAHome page
H. Kiaris, I. Chatzistamou, A. V. Schally, G. Halmos, J. L. Varga, H. Koutselini, and A. Kalofoutis
Ligand-dependent and -independent effects of splice variant 1 of growth hormone-releasing hormone receptor
PNAS, August 5, 2003; 100(16): 9512 - 9517.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 European Society of Endocrinology.